Step 1 of 2
These downloadable slides provide evidence on antibody–drug conjugates in endometrial cancer and present information about the molecular classification of endometrial cancer, algorithms for first-line and second-line therapy and data from clinical trials like GOG-3031/RUBY, NRG-GY018/KEYNOTE-868, and DUO-E/GOG-3041/ENGOT-EN10. In addition, the toxicities associated with antibody–drug conjugates are outlined. Major disparities in endometrial cancer with incidence, outcomes, and biomarkers are also highlighted.